Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- objective response rate（ORR）
研究概览
简要总结
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).
详细描述
Patients with relapsed /refractory aggressive B cell lymphoma usually have a poor prognosis. These patients cannot be treated successfully or tolered with the conventional chemotherapy. Epigenetic changes in B-cell lymphoma. Thus, epigenetic agents may offer potential improvment of clinical outcomes. Chidamide is a new type of oral histone deacetylase inhibitor. Our exploratory research found that Chidamide was effect in some relapsed /refractory B cell lymphoma patients
. Thus, we will evaluate the efficacy and safety of Chidamide in the patients with aggressive relapsed refractory B cell lymphoma failed from second line chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed as B-cell Non-Hodgkin's Lymphoma (NHL) according to "2008 WHO classification of tumors of haematopoietic and lymphoid tissues", including Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), transformed indolent lymphoma (TL), and other subtypes that investigators consider to be appropriate to be enrolled;
- •Patients achieved CR or PR in previous cytotoxic chemotherapy, and relapsed later than 6 months after remission;
- •Patients with DLBCL, FL grade3, MALT, LPL and SLL received at least two chemotherapy regimens, and Patients with FL grade1-2 received at least three chemotherapy regimens;
- •At least one measurable lesion with a longest diameter >1.5cm or a short axis >1.0cm;
- •Age18-75 years;
- •ECOG performance status 0-2;
- •Life expectancy no less than 3 months;
- •Functions within 7 days prior to enrollment: Blood routine test: Hb ≥ 80g/L, absolute neutrophil count ≥1.5 × 109/L, platelet ≥60 × 109/L; Total bilirubin ≤ 1.5 times of normal maximum, ALT/AST≤ 2.5 times of normal maximum, for patients with liver metastasis ALT/AST≤ 5 times of normal maximum; serum creatinin≤1.5 times of normal maximum or CCr≥ 60ml/min;
- •LVEF ≥ 50% by echocardiography;
- •Contraception during and 4 weeks after the study for patients at child bearing age;
- •Patients have signed the Informed Consent Form.
排除标准
- •Patients received Chidamide treatment within 6 months prior to enrollment;
- •Patients with Burkitt Lymphoma, B-lymphoblastic lymphoma, central nervous system lymphoma and HIV-Associated Lymphoma;
- •Patients with a "currently active" second malignancy;
- •Patients not recovered from non-hematologic toxicities within 4 weeks prior to enrollment due to chemotherapy, radiation and immunotherapy;
- •Patients receiving or received corticosteroids within 2 weeks prior to enrollment;
- •Patients with cumulative life time dose of Doxorubicin > 450mg/m2;
- •Patients who have been treated with any investigational drug within 4 weeks prior to enrollment;
- •Women during pregnancy or lactation;
- •Patients with active infection, medical conditions, or mental disorders;
- •Patients with active infection of HBV, HCV or HIV;
- •Congestive heart failure (NYHA grade III/IV), myocardial infarction within 6 months, QTc elongation with clinical significance (≥480ms), hypertension BP≥150/100 mmHg and symptomatic coronary heart disease that require treatment;
- •Patients with drug abuse, long term alcoholism that may impact the results of the trial;
- •Non-appropriate patients for the trial according to the judgment of the investigators.
研究组 & 干预措施
Chidamide
Chidamide should be given at a fixed time with fixed dosage
干预措施: Chidamide (Drug)
结局指标
主要结局
objective response rate（ORR）
时间窗: every 6 weeks until 2 years after last patient's enrollment
Overall response was determined on the basis of investigator assessments according to lymphoma response to immunomodulatory therapy criteria (LYRIC) for Malignant Lymphoma, 2016. Tumor assessments were performed with CT/MRI with or without PET.
次要结局
- progression-free survival（PFS）(every 6 weeks until 2 years after last patient's enrollment)
- overall survival（OS）(every 6 weeks until 2 years after last patient's enrollment)
- Percentage of Participants With Adverse Events (AEs)(Up to 36 months)
研究者
Huiqiang Huang
Chief
Sun Yat-sen University